MGA

Summary

MGA (MAX dimerization protein MGA, HGNC:14010) is a protein-coding gene on chromosome 15q15, encoding MAX gene-associated protein (Q8IWI9). Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes.

Predicted to enable DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in cell fate specification and positive regulation of transcription by RNA polymerase II. Predicted to act upstream of or within cellular response to leukemia inhibitory factor. Part of MLL1 complex.

Source: NCBI Gene 23269 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 99 total — 4 pathogenic, 1 likely-pathogenic
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 4 cancer types
• MANE Select transcript: NM_001400225

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14010
Approved symbol	MGA
Name	MAX dimerization protein MGA
Location	15q15
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0518, MAD5, MXD5, FLJ12634
Ensembl gene	ENSG00000174197
Ensembl biotype	protein_coding
OMIM	616061
Entrez	23269

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 12 protein_coding, 5 protein_coding_CDS_not_defined, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000219905, ENST00000545763, ENST00000561532, ENST00000563576, ENST00000564190, ENST00000566288, ENST00000566586, ENST00000566718, ENST00000568255, ENST00000570161, ENST00000682463, ENST00000682598, ENST00000703840, ENST00000703841, ENST00000703842, ENST00000703843, ENST00000916428, ENST00000916429, ENST00000916430, ENST00000916431, ENST00000916432

RefSeq mRNA: 5 — MANE Select: NM_001400225 NM_001080541, NM_001164273, NM_001400225, NM_001400242, NM_001400243

CCDS: CCDS55959, CCDS55960, CCDS91982

Canonical transcript exons

ENST00000703841 — 24 exons

Exon	Start	End
ENSE00000676928	41699064	41699159
ENSE00000884069	41698863	41698941
ENSE00000884071	41707728	41707859
ENSE00000884072	41708104	41708208
ENSE00000884073	41710691	41711349
ENSE00001226338	41764886	41765062
ENSE00001379445	41762129	41762362
ENSE00001507293	41760323	41760529
ENSE00001507294	41757788	41757839
ENSE00001507295	41754437	41754567
ENSE00001507296	41749111	41750615
ENSE00001507299	41742546	41743172
ENSE00001654253	41696075	41697023
ENSE00001667590	41748637	41748927
ENSE00001762919	41668828	41669958
ENSE00002595159	41739906	41740203
ENSE00003550063	41761739	41761850
ENSE00003990062	41766004	41769940
ENSE00003990063	41727180	41727406
ENSE00003990067	41713151	41713496
ENSE00003990069	41734522	41734594
ENSE00003990070	41729164	41729349
ENSE00003990073	41736181	41736698
ENSE00003990076	41660405	41660525

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 95.28.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.1425 / max 217.9673, expressed in 1800 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
146203	14.5032	1692
146201	2.6832	882
146204	2.1742	1046
146200	1.5903	790
146202	0.1916	87

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.28	gold quality
oocyte	CL:0000023	94.74	gold quality
tendon	UBERON:0000043	94.19	gold quality
tendon of biceps brachii	UBERON:0008188	94.00	gold quality
adrenal tissue	UBERON:0018303	93.70	gold quality
secondary oocyte	CL:0000655	92.25	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.00	gold quality
corpus callosum	UBERON:0002336	91.46	gold quality
medial globus pallidus	UBERON:0002477	90.52	gold quality
sperm	CL:0000019	89.91	gold quality
sural nerve	UBERON:0015488	89.87	gold quality
pylorus	UBERON:0001166	88.94	gold quality
globus pallidus	UBERON:0001875	88.51	gold quality
nipple	UBERON:0002030	88.48	gold quality
colonic epithelium	UBERON:0000397	87.84	gold quality
inferior vagus X ganglion	UBERON:0005363	87.83	gold quality
male germ cell	CL:0000015	87.78	gold quality
cardia of stomach	UBERON:0001162	87.17	gold quality
bone marrow cell	CL:0002092	86.63	gold quality
ventricular zone	UBERON:0003053	85.68	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.08	gold quality
ventral tegmental area	UBERON:0002691	84.97	gold quality
cortical plate	UBERON:0005343	84.84	gold quality
renal medulla	UBERON:0000362	84.24	gold quality
superficial temporal artery	UBERON:0001614	84.23	gold quality
endometrium	UBERON:0001295	84.03	gold quality
superior vestibular nucleus	UBERON:0007227	83.39	gold quality
tonsil	UBERON:0002372	83.36	gold quality
ganglionic eminence	UBERON:0004023	82.92	gold quality
superior surface of tongue	UBERON:0007371	82.40	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.69
E-GEOD-124858	no	321.56

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA0801.1	MGA	TBX6-related factors
MA1960.1	MGA::EVX1	TBX6-related factors::HOX
MA1960.2	MGA::EVX1	TBX6-related factors::HOX

JASPAR matrix evidence (PMIDs): PMID:12093383, PMID:24218641

Literature-anchored findings (GeneRIF, showing 8)

• TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection. (PMID:24131248)
• Results show that inactivation of MGA was observed in both non-small cell lung cancer and SCLC. (PMID:24362264)
• In conclusion, our study generated five mAbs against MGA and identified the best candidate for detection of MGA expression in breast cancer tissues. (PMID:26272389)
• we suggest that MGA loss-of-function mutations are present in colorectal cancers (PMID:27306572)
• this study shows that LINE1 contributes to autoimmunity through both RIG-I- and MDA5-mediated RNA sensing pathways (PMID:29525183)
• Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma. (PMID:31862696)
• Functional characterization of cooperating MGA mutations in RUNX1::RUNX1T1 acute myeloid leukemia. (PMID:38454121)
• In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer. (PMID:39298484)

Cross-species orthologs

14 orthologs

Organism	Symbol	Gene ID
danio_rerio	mgaa	ENSDARG00000078784
mus_musculus	Mga	ENSMUSG00000033943
rattus_norvegicus	Mga	ENSRNOG00000006378
drosophila_melanogaster	H15	FBGN0016660
drosophila_melanogaster	mid	FBGN0261963
drosophila_melanogaster	ocm	FBGN0266083
caenorhabditis_elegans		WBGENE00003106
caenorhabditis_elegans		WBGENE00004750
caenorhabditis_elegans		WBGENE00006545
caenorhabditis_elegans		WBGENE00006546
caenorhabditis_elegans		WBGENE00006556
caenorhabditis_elegans		WBGENE00006557
caenorhabditis_elegans		WBGENE00006559
caenorhabditis_elegans		WBGENE00044798

Paralogs (16): TBX21 (ENSG00000073861), TBX5 (ENSG00000089225), TBX15 (ENSG00000092607), TBX18 (ENSG00000112837), TBX2 (ENSG00000121068), TBX4 (ENSG00000121075), TBX22 (ENSG00000122145), TBX3 (ENSG00000135111), TBR1 (ENSG00000136535), TBX19 (ENSG00000143178), TBX6 (ENSG00000149922), EOMES (ENSG00000163508), TBXT (ENSG00000164458), TBX20 (ENSG00000164532), TBX10 (ENSG00000167800), TBX1 (ENSG00000184058)

Protein

Protein identifiers

MAX gene-associated protein — Q8IWI9 (reviewed: Q8IWI9)

Alternative names: MAX dimerization protein 5

All UniProt accessions (7): Q8IWI9, A0A8C8P5L8, A0A994J443, A0A994J4J1, A0A994J6L2, H3BP52, H3BU53

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5’-AATTTCACACCTAGGTGTGAAATT-3’ core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerization with MAX. This heterodimerization serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor.

Subunit / interactions. Interacts with MAX. Requires dimerization with MAX for E-box binding. Component of some MLL1/MLL complex, at least composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the facultative components BACC1, CHD8, E2F6, HSP70, INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, MYST1/MOF, PELP1, PHF20, PRP31, RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9 and TEX10. Interacts with ZMYND11.

Subcellular location. Nucleus.

Tissue specificity. Highly expressed in germ cells and granulosa cells.

Disease relevance. Premature ovarian failure 26 (POF26) [MIM:621065] A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF26 inheritance is autosomal dominant. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. Transcription repression is enhanced or dependent on the presence of the T-box DNA-binding domain.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IWI9-4	1	yes
Q8IWI9-3	2

RefSeq proteins (4): NP_001074010, NP_001157745, NP_001387154, NP_001387171 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001699	TF_T-box	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR011598	bHLH_dom	Domain
IPR018186	TF_T-box_CS	Conserved_site
IPR032060	MGA_dom	Domain
IPR036638	HLH_DNA-bd_sf	Homologous_superfamily
IPR036960	T-box_sf	Homologous_superfamily
IPR037935	MAX_gene-associated_bHLHzip	Domain
IPR046360	T-box_DNA-bd	Domain

Pfam: PF00010, PF00907, PF16059

UniProt features (108 total): cross-link 47, compositionally biased region 16, region of interest 13, modified residue 13, sequence variant 7, sequence conflict 6, coiled-coil region 2, chain 1, domain 1, DNA-binding region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q8IWI9 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (60): 534, 607, 645, 851, 924, 1208, 1430, 1457, 2265, 2541, 2910, 2921, 2978, 4, 178, 323, 329, 349, 432, 460 …

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-8953750	Transcriptional Regulation by E2F6
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 203 (showing top): MORF_BRCA1, MORF_ATRX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MORF_ESR1, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, MORF_RAD51L3, MODULE_313, MARTINEZ_RB1_TARGETS_UP, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, GOCC_NUCLEAR_UBIQUITIN_LIGASE_COMPLEX, GOBP_CELL_FATE_SPECIFICATION, MORF_ATF2, GOBP_CHROMATIN_REMODELING, MODULE_207

GO Biological Process (4): cell fate specification (GO:0001708), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of DNA-templated transcription (GO:0045893), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (6): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), protein dimerization activity (GO:0046983), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), MLL1 complex (GO:0071339), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Generic Transcription Pathway	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
cell fate commitment	1
cellular developmental process	1
transcription by RNA polymerase II	1
positive regulation of RNA biosynthetic process	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
protein binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
MLL1/2 complex	1
cellular_component	1

Protein interactions and networks

STRING

1147 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MGA	MAX	P25912	828
MGA	MAVS	Q7Z434	700
MGA	L3MBTL2	Q969R5	627
MGA	TBK1	Q9UHD2	549
MGA	DHX58	Q96C10	532
MGA	TANK	Q92844	513
MGA	TRAF3	Q13114	511
MGA	IFIH1	Q9BYX4	507
MGA	MXD4	Q14582	478
MGA	RIGI	O95786	474
MGA	L3MBTL1	Q9Y468	460
MGA	E2F6	O75461	427
MGA	MNT	Q99583	420
MGA	PCGF6	Q9BYE7	418
MGA	MXD1	Q05195	412

IntAct

211 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
WDR5	KMT2D	psi-mi:“MI:0914”(association)	0.910
RYBP	CSNK2A2	psi-mi:“MI:0914”(association)	0.900
CDK8	MED19	psi-mi:“MI:2364”(proximity)	0.850
RYBP	BMI1	psi-mi:“MI:0914”(association)	0.850
MAX	MGA	psi-mi:“MI:0915”(physical association)	0.850
HDAC1	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
HDAC1	TNRC18	psi-mi:“MI:0914”(association)	0.790
E2F6	WDR5	psi-mi:“MI:0914”(association)	0.730
L3MBTL2	E2F6	psi-mi:“MI:0914”(association)	0.730
RING1	CBX4	psi-mi:“MI:0914”(association)	0.730
RNF2	E2F6	psi-mi:“MI:0914”(association)	0.730
MAX	E2F6	psi-mi:“MI:0914”(association)	0.710
NFIC	NFIB	psi-mi:“MI:2364”(proximity)	0.690
HSPB2	BAG3	psi-mi:“MI:0914”(association)	0.670
PCGF6	CBX4	psi-mi:“MI:0914”(association)	0.640
YAF2	E2F6	psi-mi:“MI:0914”(association)	0.640
CBX3	E2F6	psi-mi:“MI:0914”(association)	0.640
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
PRPS1	NMT2	psi-mi:“MI:0914”(association)	0.640

BioGRID (347): MGA (Protein-peptide), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS), MGA (Affinity Capture-MS)

ESM2 similar proteins: A0A140LFM6, A0A1B0GVH6, A0A1L8H8C0, A0A2K1JJ00, A0JMD2, A2ARZ3, A2AWL7, A4IGV6, A6H5Y1, D3ZJ47, E9Q309, F1QPR4, F5H4B4, H0WFA5, O14513, O35413, O94875, P0CAX8, P48437, Q12912, Q15468, Q1LXZ9, Q1X8D7, Q28FG2, Q3UTJ2, Q3ZBS1, Q499E5, Q49A88, Q4V7H1, Q5T5U3, Q5VT06, Q62417, Q62770, Q69Z38, Q6DFB0, Q80TY4, Q8BLN6, Q8CB14, Q8IWI9, Q8K0T7

Diamond homologs: A1YF56, A2AWL7, D3ZJK7, E1BEA8, O01409, O13161, O15119, O15178, O17212, O43435, O54839, O60806, O70306, O73718, O75333, O95935, O95936, O95947, P20293, P24781, P55965, P56158, P57082, P70323, P70324, P70325, P70326, P70327, P79742, P79777, P79778, P79779, P79944, P80492, P87377, P90971, Q07998, Q13207, Q16650, Q17134

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MAX	“up-regulates activity”	MGA	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 211 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transcriptional Regulation by E2F6	13	26.2×	7e-13
Transcription of E2F targets under negative control by DREAM complex	5	18.8×	3e-04
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	9	18.6×	1e-07
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	6	15.2×	2e-04
G0 and Early G1	5	15.2×	8e-04
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	6	12.8×	4e-04
Regulation of endogenous retroelements	5	12.7×	1e-03
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	12	12.1×	5e-08

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	6	12.8×	1e-03
positive regulation of miRNA transcription	8	12.4×	4e-05
bone development	6	8.8×	5e-03
heterochromatin formation	6	8.2×	7e-03
double-strand break repair	7	7.6×	4e-03
chromatin remodeling	19	7.4×	3e-09
transcription by RNA polymerase II	19	7.1×	5e-09
DNA damage response	13	3.7×	5e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 4 cancer types — CLLSLL, LUAD, PLMESO, PRAD.

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	30
Likely benign	12
Benign	12

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3573022	NM_001400225.1(MGA):c.2709_2712del (p.Ala905fs)	Pathogenic
3573023	NM_001400225.1(MGA):c.2728C>T (p.Arg910Ter)	Pathogenic
3573024	NM_001400225.1(MGA):c.1673del (p.Asp558fs)	Pathogenic
585331	der(15)t(5:15)(q23.2;q15.1)	Pathogenic
800331	NM_001400225.1(MGA):c.3733G>C (p.Glu1245Gln)	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000001663 (15:41667920 C>T), RS1000023361 (15:41738838 C>A,T), RS1000025799 (15:41738014 A>G), RS1000034922 (15:41624680 G>A), RS1000062825 (15:41705547 A>G), RS1000072556 (15:41705879 G>A), RS1000082909 (15:41746023 C>G), RS1000126705 (15:41704612 C>A,G,T), RS1000148127 (15:41667320 C>G,T), RS1000173441 (15:41717580 A>G), RS1000218375 (15:41763730 C>G,T), RS1000220810 (15:41682579 C>A,T), RS1000220851 (15:41673760 C>A), RS1000248133 (15:41711642 AC>A), RS1000256514 (15:41654956 G>T)

Disease associations

OMIM: gene MIM:616061 | disease phenotypes: MIM:621065, MIM:254500

GenCC curated gene-disease

Mondo (3): premature ovarian failure 26 (MONDO:0976129), spindle cell sarcoma (MONDO:0002927), plasma cell myeloma (MONDO:0009693)

Orphanet (2): Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, increases expression, decreases expression	3
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, decreases expression	3
Tretinoin	affects expression, decreases expression	2
Valproic Acid	decreases expression, affects expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases activity, increases expression, affects binding	1
beta-lapachone	decreases expression	1
sodium arsenite	affects methylation	1
butyraldehyde	increases expression	1
coumarin	decreases phosphorylation	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Caffeine	affects phosphorylation	1
Coumestrol	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Doxorubicin	decreases expression	1
Endosulfan	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Quercetin	decreases expression	1
Vincristine	increases expression	1
Lactic Acid	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B5EI	BOD-DSRCT	Cancer cell line

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00104104	PHASE4	COMPLETED	A Multiple Myeloma Trial in Patients With Bone Metastases
NCT00211211	PHASE4	COMPLETED	FREE Study - Fracture Reduction Evaluation
NCT00242528	PHASE4	WITHDRAWN	Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
NCT00257114	PHASE4	COMPLETED	Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00352703	PHASE4	COMPLETED	PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
NCT00361140	PHASE4	COMPLETED	Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
NCT00622505	PHASE4	COMPLETED	Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
NCT00652041	PHASE4	COMPLETED	Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma
NCT00733538	PHASE4	COMPLETED	Stage I Multiple Myeloma Treatment
NCT01087008	PHASE4	COMPLETED	Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
NCT01249690	PHASE4	UNKNOWN	Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
NCT01410929	PHASE4	WITHDRAWN	Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma
NCT01731886	PHASE4	COMPLETED	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
NCT01868828	PHASE4	UNKNOWN	A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma
NCT02268890	PHASE4	COMPLETED	A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma
NCT02286830	PHASE4	COMPLETED	Prolonged Protection From Bone Disease in Multiple Myeloma
NCT02559154	PHASE4	UNKNOWN	Modified Bortezomib-based Combination Therapy for Multiple Myeloma
NCT02577783	PHASE4	UNKNOWN	PDD vs PAD to Treat Initially Diagnosed MM
NCT02773550	PHASE4	TERMINATED	Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02958969	PHASE4	COMPLETED	Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
NCT03173092	PHASE4	TERMINATED	A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03619252	PHASE4	COMPLETED	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT03908138	PHASE4	UNKNOWN	RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma
NCT04217967	PHASE4	COMPLETED	Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
NCT04952766	PHASE4	COMPLETED	Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
NCT04989140	PHASE4	UNKNOWN	Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
NCT05183139	PHASE4	WITHDRAWN	A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
NCT05201781	PHASE4	RECRUITING	A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05429515	PHASE4	NOT_YET_RECRUITING	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT05545202	PHASE4	UNKNOWN	A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
NCT05555329	PHASE4	COMPLETED	Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study
NCT05722405	PHASE4	RECRUITING	Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05855122	PHASE4	UNKNOWN	Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05944783	PHASE4	NOT_YET_RECRUITING	Bioequivalence Studies of Dasatinib 100 Mg
NCT06057402	PHASE4	RECRUITING	Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06251076	PHASE4	RECRUITING	Plan Development for Giving Teclistamab in the Outpatient Setting